Cambridge Investment Research Advisors
IRD

Cambridge Investment Research Advisors’s Opus Genetics IRD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-38
Closed -$9K – 1991
2017
Q1 		$9K Buy
38
+17
+81% +$2.2K ﹤0.01% 1764
2016
Q4 		$1K Sell
21
-50
-70% -$4.07K ﹤0.01% 1665
2016
Q3 		$7K Hold
71
– – ﹤0.01% 1737
2016
Q2 		$9K Hold
71
– – ﹤0.01% 1549
2016
Q1 		$11K Hold
71
– – ﹤0.01% 1597
2015
Q4 		$12K Buy
71
+46
+184% +$9.78K ﹤0.01% 1564
2015
Q3 		$6K Hold
25
– – ﹤0.01% 1431
2015
Q2 		$7K Buy
+25
New +$8.49K ﹤0.01% 1438

Other funds holding IRD

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Cambridge Investment Research Advisors's IRD Position: Q2 2017 in Review

Cambridge Investment Research Advisors sold out of Opus Genetics (IRD) in Q2 2017, closing a stake of 38 shares — an estimated $9K sold.

Cambridge Investment Research Advisors first reported a position in IRD in Q2 2015 and held it in 8 quarters. The position peaked at $12K in Q4 2015. 23 funds tracked by Wall St. Rank hold IRD as of Q2 2017.

  • Cambridge Investment Research Advisors reported no remaining Opus Genetics position as of Q2 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 38 Opus Genetics shares in Q2 2017, an estimated $9K.
  • Cambridge Investment Research Advisors first reported a position in Opus Genetics in Q2 2015 and held it in 8 quarters.
  • Cambridge Investment Research Advisors's Opus Genetics position peaked at $12K in Q4 2015.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2017, filed 8 Aug 2017.